New Stock News | FangTuo Bio
According to the Hong Kong Stock Exchange disclosure on August 28, Frontera Therapeutics (referred to as Fangtuo Biomedical) submitted a listing application to the main board of the Hong Kong Stock Exchange, with UBS Group and Haitong International as its joint sponsors.
According to a disclosure by the Hong Kong Stock Exchange on August 28, Frontera Therapeutics (abbreviated as: ) submitted a listing application to the main board of the Hong Kong Stock Exchange, with UBS Group and HAITONG INT'L as its joint sponsors. The prospectus indicates that Frontera Therapeutics is a clinical-stage gene therapy company dedicated to the independent development of recombinant adeno-associated virus (rAAV) gene therapies. The company's pipeline particularly focuses on ophthalmic and cardiovascular diseases. The company has established the rAAV gene therapy R&D platform (EXACTE) to screen candidate drugs with better tissue tropism, high transduction efficiency, long-term efficacy, and excellent safety.
Related Articles
HK Stock Market Move |
Huachuang Securities: Small and medium-sized brokerages still possess cyclical elasticity, and product capability determines development space.
HK Stock Market Move | Shenzhen Longsys Electronics (09976) rose over 7% in early trading, with a net profit exceeding 10 billion in the first half of the year. The company is a leading domestic memory module manufacturer.
HK Stock Market Move |
Huachuang Securities: Small and medium-sized brokerages still possess cyclical elasticity, and product capability determines development space.
HK Stock Market Move | Shenzhen Longsys Electronics (09976) rose over 7% in early trading, with a net profit exceeding 10 billion in the first half of the year. The company is a leading domestic memory module manufacturer.
RECOMMEND
